Anti-Entamoeba Histolytica [Clone EH34.5]

Entamoeba histolytica HK-9

This monoclonal antibody is supplied as a highly purified liquid in Phosphate Buffered Saline (PBS), pH 7.2–7.4. It is entirely carrier-free (no BSA or gelatin) and preservative-free (no sodium azide), ensuring zero interference with downstream labeling, conjugation, or cell-based functional assays.

Liquid

Antibodies are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. All lots of Clone EH34.5 are manufactured, purified, and quality-tested entirely at our state-of-the-art facility in St. Louis, Missouri, USA. Operating under strict ISO 9001 and ISO 13485 (Medical Devices) Quality Management Systems, we guarantee the complete lot-to-lot consistency, full documentation traceability, and security of supply required to scale this clone from research validation into commercial IVD production.

This antibody is stable for at least one (1) year at -20°C to -70°C. Store product in appropriate aliquots to avoid multiple freeze-thaw cycles.

Next Day 2-8°C

Clone EH34.5 exhibits robust affinity for both the active, tissue-dissolving trophozoite stage and the dormant, infective cyst stage of E. histolytica.

High-Affinity Monoclonal Antibody for Amoebiasis Diagnostic & Vaccine Pipelines

Entamoeba histolytica is an anaerobic parasitic protozoan that predominantly infects humans and other primates causing amoebiasis. In the vast majority of cases, infection is asymptomatic and the carrier is unaware they are infected. However, in an estimated 10% of cases E. histolytica causes disease. Once the trophozoites are excysted they colonize the large bowel, remaining on the surface of the mucus layer and feeding on bacteria and food particles. Occasionally, and in response to unknown stimuli, trophozoites move through the mucus layer where they come in contact with the epithelial cell layer and start the pathological process.

Cooney J, Siakavellas SI, Chiodini PL, Mahadeva U, Godbole G, Pollok RC, Smith PJ. Recent advances in the diagnosis and management of amoebiasis. Frontline Gastroenterol. 2024 Oct 7;16(1):e102554. doi: 10.1136/flgastro-2023-102554. Erratum in: Frontline Gastroenterol. 2025 Apr 8;16(3):e2. doi: 10.1136/flgastro-2023-102554corr1. PMID: 41809248; PMCID: PMC12969968.